New Human Trial on Oleoylethanolamide Ingredient Shows Rapid Incretin Hormone Response

A newly published human trial on Trpti, a bioavailable oleoylethanolamide ingredient developed by Saanroo, found that a single 300 mg dose produced measurable increases in two incretin hormones, glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, within 15 minutes of ingestion.^1,2

The study adds mechanistic detail to a growing body of Trpti-specific research, at a time when incretin biology has become one of the most closely watched areas of metabolic health research following the broader rise of GLP-1-targeted pharmaceuticals.

"The publication marks an important milestone in Saanroo's expanding body of clinical research on Trpti," said Pavitra Viswanath, Saanroo’s director of clinical affairs and a co-author of the study. "While previous clinical studies demonstrated meaningful benefits for healthy weight management, gut microbiome composition, and gut barrier integrity, this latest research helps explain one of the underlying biological mechanisms behind those outcomes by showing that Trpti supports the body's natural post-meal incretin response following supplementation."

What Did the Clinical Trial Actually Measure?

The trial was a fixed-sequence, single-blind, placebo-controlled, three-period crossover study enrolling 37 healthy adults with a body mass index between 25.0 and 34.9 kg/m². Participants received a single dose of placebo, 150 mg Trpti, or 300 mg Trpti following an overnight fast, with blood samples collected over 8 hours and standardized meals provided at 15 minutes and 4 hours post-dose.²

Researchers tracked time-course responses of GLP-1, GIP, dipeptidyl peptidase-4, insulin, glucose, and glucagon. According to the published results, GLP-1 concentrations were approximately 20% to 25% higher than placebo at key post-dosing timepoints in the 300 mg group, with similar increases observed for GIP.² Participants receiving Trpti also consumed significantly less of a standardized test meal compared with those receiving placebo, and all safety biomarkers remained within normal clinical ranges across both dose groups.

How Does Oleoylethanolamide Relate to the Broader Incretin and Weight Management Research Landscape?

Oleoylethanolamide is an endogenous lipid produced in the small intestine during dietary fat absorption, where it functions as a gut-to-brain satiety signal and has been studied as a potential target for obesity-related interventions independent of any single commercial ingredient.³

Endogenous oleoylethanolamide synthesis has been reported to decline in states of obesity and insulin resistance, which is the physiological rationale generally cited for exogenous supplementation approaches like Trpti.

This new trial builds on an earlier 12-week randomized, double-blind, placebo-controlled study of Trpti in 57 adults with obesity, which found increased abundance of the beneficial gut bacteria Akkermansia muciniphila and Faecalibacterium prausnitzii alongside statistically significant weight reduction in participants with a body mass index ranging from 30 to 40, compared with placebo.⁴

How Should This Data Be Interpreted, and What Should Manufacturers Note About It?

The acute, single-dose design of this trial means it demonstrates a rapid physiological response rather than a sustained clinical outcome like weight loss, which was the focus of the separate 12-week trial referenced above. Manufacturers evaluating claims tied to this research should distinguish between the mechanistic evidence shown here, meaning hormone-level changes within hours of dosing, and the longer-term efficacy outcomes demonstrated in Saanroo's separate multi-week trial, since the 2 studies answer different questions.

References

1. New peer-reviewed clinical study shows Trpti supports the body's natural incretin response. Saanroo. August 4, 2026. Accessed August 5, 2026. Press release provided via email.

2. Briskey D, Pellow J, Viswanath P, Rao A. Acute TRPTI (oleoylethanolamide) supplementation enhances incretin hormone responses: a fixed-sequence crossover study. Front Endocrinol. 2026;17:1879799. doi:10.3389/fendo.2026.1879799

3. Romano A, Friuli M, Eramo B, et al. "To brain or not to brain": evaluating the possible direct effects of the satiety factor oleoylethanolamide in the central nervous system. Front Endocrinol. 2023;14:1158287. doi:10.3389/fendo.2023.1158287

4. Batacan R, Rao A, Bajagai YS, Stanley D, Briskey D. Oleoylethanolamide supplementation enriches Akkermansia muciniphila and modulates intestinal barrier function in adults with obesity: a randomized, double-blind, placebo-controlled trial. Gut Microbes Rep. 2026;3(1):2622259. doi:10.1080/29933935.2026.2622259